MagBio Genomics Inc. Develops Automated RNA Purification Chemistry for Mawi iSWAB-RNA v2 on Thermofisher KingFisher™ Flex
11.5.2021 16:00:00 EEST | Business Wire | Press release
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MagBio Genomics has successfully developed an automated RNA purification method for iSWAB-RNA v2 on the Thermofisher KingFisher™ Flex platform with its HighPrep™ Total RNA Isolation Kit - iSWAB™.
Mawi DNA Technologies’ iSWAB-RNA v2 allows for non-invasive self collection, concentration, and stabilization of intact buccal cells and/or any mammalian cells collected with a swab or cytobrush. It enables up to four weeks of real-time ambient stabilization of total RNA from the point of collection to processing. The high-quality RNA extracted from stabilized iSWAB-RNA v2 samples is suitable for gene expression applications such as real-time quantitative PCR, reverse transcription PCR, microarrays, northern blot analysis, nuclease protection assays, cDNA library construction and RNA-seq.
“Collaborating with MagBio Genomics to optimize their HighPrep™ Total RNA Plus Kit-iSWAB™ for iSWAB-RNA v2 was a no-brainer for us, especially because it provides a great option for our high throughput end users like pharma and CROs,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies. “Partnerships with leaders in nucleic acid purification chemistries with a global presence, such as MagBio Genomics, are increasing worldwide access of our sample collection technologies, which results in better understanding of health and wellness at a global rather than at a regional level.” El-Fahmawi said that due to increased sample sizes in cohort genetic population studies, there is an increasing need for automated RNA purification solutions. The MagBio HighPrep Total RNA Plus Kit-iSWAB™ simplifies this research step, which can be labor-intensive.
“MagBio has successfully developed and optimized the HighPrep™ Total RNA Isolation Kit-iSWAB™ for extraction of total RNA from iSWAB-RNA v2 samples on Thermofisher KingFisher™ Flex Purification System,” said Dr. Mothomang Mlalazi-Oyinloye, Associate Scientific Director, MagBio Genomics. “This new method is being used by a major pharmaceutical company to process iSWAB-RNA v2 samples for elucidation of molecular mechanisms of cancer development. With this automated protocol, 96 samples can be run in less than one hour.” She added that the extracted RNA is of high purity and quality and is compatible with complex and sensitive assays. RNA yields up to 1ug per sample are obtained (Qubit RNA Broad Assay).
“We are expanding our automated methods library to include the most commonly used lab automation systems,” Dr. Mlalazi-Oyinloye said. “iSWAB-RNA v2 is the non-invasive sample collection alternative to venipuncture and tissue biopsy our fellow researchers have been looking for which maintains RNA integrity especially during long transit times. MagBio Genomics is all about making the next generation sequencing workflow better. We developed an automated method for simplifying RNA purification from iSWAB-RNA v2 samples using our HighPrep™ Total RNA Plus Kit-iSWAB™,” said Dr. Hyacinth Ntchobo, CEO, MagBio Genomics. He added that when used in combination, Mawi’s iSWAB-RNA v2 collection technology and MagBio Genomics’ purification chemistry provide an efficient workflow for high throughput purification of high-quality RNA for demanding downstream applications.
About MagBio Genomics Inc.
MagBio Genomics is a global company that develops and commercializes magnetic bead-based products for nucleic acid isolation including biomarkers as tools for liquid biopsy genomic research. The current focus encompasses products that cover the complete sample preparation for NGS; from allowing safeguarding integrity of bio-samples, efficient isolation of circulating biomarkers to target enrichment from biological samples. Products are applied to human genetic research including cancer genomic studies and non-invasive prenatal testing (NIPT).“WE SIMPLY MAKE NGS BETTER.” For more information, visit http://www.magbiogenomics.com.
About Mawi DNA Technologies
Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. Mawi DNA has established relationships with children’s hospitals for neonatal screening and has an extensive global network of international distributors to market and sell iSWAB products. For more information, visit http://www.mawidna.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005456/en/
Contact information
Susan Tellem, APR, RN, BSN
310-313-3444 x1, Susan@tellemgrodypr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQOS One of the Most Valuable Global Brands, According to Kantar’s BrandZ 2026 Ranking26.5.2026 11:00:00 EEST | Press release
Philip Morris International’s (PMI) (NYSE: PM) IQOS, the #1 tobacco heating system1, has been listed for the first time as one of the top 100 most valuable brands in the world in Kantar’s BrandZ 2026 Most Valuable Global Brands. This ranking solidifies IQOS’s global momentum and its emergence as a culturally relevant, iconic brand for adult nicotine users seeking better alternatives to cigarettes. According to the BrandZ 2026 Most Valuable Global Brands, IQOS achieved a ranking of #74 globally. With more than 35 million IQOS users worldwide—most of whom have fully switched away from cigarettes2—the brand continues to lead from the front and champion in a smoke-free era through science-backed innovation and consumer-centric design. Within 10 years of inception, IQOS surpassed $10 billion in annual net revenues, reaching this milestone faster than some of the world’s most recognized technology companies—and making up the large majority of Philip Morris International’s smoke-free business
Quectel Expands EMEA Reach With Future Electronics Distribution Agreement26.5.2026 11:00:00 EEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced an expanded distribution partnership with Future Electronics to bring its full portfolio of products and services to customers across the EMEA region. Under this agreement, Future Electronics will bring Quectel’s full IoT portfolio to customers across Europe, the Middle East and Africa, with a strong focus on its non-cellular solutions, including antennas, GNSS, Wi-Fi, Bluetooth and smart modules. This collaboration marks a significant step in strengthening Quectel’s presence in EMEA, leveraging Future Electronics’ strong regional infrastructure, technical expertise, and established customer relationships to accelerate growth and innovation. “Future Electronics’ extensive footprint and demand creation capabilities make them an ideal partner for expanding our reach across EMEA,” said Natasha Barrios, Senior Vice President, EMEA, Quectel Wireless Solutions. “By working together, we can ensure faster a
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 10:00:00 EEST | Press release
Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercialization in the licensed territory under a jointly agreed China Development Plan. Merz will act as Overseas Holder of the Drug Registration Certificate and Kvvit will serve as Domestic Responsible Person, funding local clinical development and regulatory submissions. INBRIJA® is currently not approved in China, Hong Kong and Macao
Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 09:49:00 EEST | Press release
Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weydenthal, Rector of Poznań University of Technology Prof. Teofil Jesionowski, and industry leaders mark the occasion. The installation of the IQM Radiance R1 system at the university aligns with the strategic objectives outlined in Poland’s quantum technology development roadmap, as well as broader European initiatives in this area. Poland has a strong foundation in quantum technologies, particularly in STEM (Science, Technology, Engineering, and Mathematics) disciplines, built on high academic
BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 09:30:00 EEST | Press release
BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical scenarios. All data remains in Austria and therefore within European jurisdiction, helping organizations protect themselves from geopolitical risks, arbitrary price changes by international hyperscalers, and the risk of external shutdowns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525934244/en/ With its own data center in Graz, the BearingPoint Fully-Owned Sovereign Infrastructure Stack enables companies and publ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
